Pharsight

1. List of Contrave drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11278544	NALPROPION	Compositions for affecting weight loss	Apr, 2024 (10 months from now)
US8815889	NALPROPION	Compositions and methods for increasing insulin sensitivity	Jul, 2024 (1 year, 1 month from now)
US7462626	NALPROPION	Compositions for affecting weight loss	Jul, 2024 (1 year, 1 month from now)
US7375111	NALPROPION	Compositions for affecting weight loss	Mar, 2025 (1 year, 9 months from now)
US9107837	NALPROPION	Sustained release formulation of naltrexone	Jun, 2027 (4 years from now)
US8318788	NALPROPION	Layered pharmaceutical formulations	Nov, 2027 (4 years from now)
US10307376	NALPROPION	Methods for administering weight loss medications	Nov, 2027 (4 years from now)
US8722085	NALPROPION	Methods for administering weight loss medications	Nov, 2027 (4 years from now)
US9125868	NALPROPION	Methods for administering weight loss medications	Nov, 2027 (4 years from now)
US8088786	NALPROPION	Layered pharmaceutical formulations	Feb, 2029 (5 years from now)
US11324741	NALPROPION	Methods for treating visceral fat conditions	May, 2029 (5 years from now)
US8916195	NALPROPION	Sustained release formulation of naltrexone	Feb, 2030 (6 years from now)
US11033543	NALPROPION	Methods of providing weight loss therapy in patients with major depression	Jan, 2031 (7 years from now)
US9248123	NALPROPION	Methods of providing weight loss therapy in patients with major depression	Jan, 2032 (8 years from now)
US10403170	NALPROPION	Methods of treating overweight and obesity	Jun, 2033 (10 years from now)
US11139056	NALPROPION	Methods of treating overweight and obesity	Jun, 2033 (10 years from now)
US9633575	NALPROPION	Methods of treating overweight and obesity	Jun, 2033 (10 years from now)
US10835527	NALPROPION	Compositions and methods for reducing major adverse cardiovascular events	Jul, 2034 (11 years from now)
US10828294	NALPROPION	Compositions and methods for weight loss in at risk patient populations	Jul, 2034 (11 years from now)
US10231964	NALPROPION	Compositions and methods for weight loss in at risk patient populations	Jul, 2034 (11 years from now)

Do you want to check out CONTRAVE patents from before 2022?

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity; For effect on blood glucose parameters in patients with insulin resistance; Use of naltrexone and bupropion in extended-release form f...

Dosage: TABLET, EXTENDED RELEASE;ORAL